Abstractbeiträge (selektiert)

2018

D. Tuerk, N. Hanke, T. Lehr. Physiologically-based pharmacokinetic modeling of gemfibrozil drug-drug interactions with the CYP2C8 victim drugs repaglinide and pioglitazone. 27th Population Approach Group Europe (PAGE), May 2018, Montreux, Switzerland

H. Britz, N. Hanke, T. Lehr. Physiologically-based pharmacokinetic (PBPK) modeling of the strong CYP1A2 inhibitor fluvoxamine. 27th Population Approach Group Europe (PAGE) meeting, May 2018, Montreux, Switzerland

K.M. Götz,  J.T. Bittenbring, T. Lehr. A systems medicine modeling approach for understanding the underlying processes of hematopoietic stem cell transplantation. Annual Meeting of the Central European Society for Anticancer Drug Research (CESAR), 2018, Berlin, Germany

K. Och, K.M. Götz, J. Rauch, K. Rohm, U. Schwarz, S. Theobald, Y. Braun, S. Kiefer, N. Pfeifer, L. Handl, S. Smola, M. Ihle, A. Turki, J. Rissland, J.T. Bittenbring, N. Graf, D. Beelen, G. Weiler, T. Lehr. XplOit – Semantic support for predictive modeling in systems medicine. Annual Meeting of the Central European Society for Anticancer Drug Research (CESAR), 2018, Berlin, Germany

K. Och, J.T. Bittenbring, T. Lehr. A population pharmacokinetic/pharmacodynamic approach to characterize the nephrotoxicity of cyclosporine in patients after hematopoietic stem cell transplantation. Annual meeting of the Central European Society for Anticancer Drug Research (CESAR), 2018, Berlin, Germany

2017

C. Dings, N. Scherer, J. Freijer, V. Nock, T. Lehr. Mathematical modeling of glucose, insulin and c-peptide during the OGTT in pre-diabetic subjects: a DIRECT study. 26th Population Approach Group Europe (PAGE), June 2017, Budapest, Hungary

N. Scherer, C. Dings, J. Freijer, V. Nock, T. Lehr. A population pharmacokinetic (PK) model of metformin regarding immediate and extended release formulations under fasted and fed conditions. 26th Population Approach Group Europe (PAGE), June 2017, Budapest, Hungary

D. Tuerk, N. Hanke, T. Lehr. Physiologically-based pharmacokinetic (PBPK) modeling of the CYP2C8 substrate pioglitazone. 26th Population Approach Group Europe (PAGE), June 2017, Budapest, Hungary

D. Moj, H. Britz, G. Egerer, W.E. Haefeli, T. Lehr. Application of a physiologically-based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat to improve dosing regimens in adults. 26th Population Approach Group Europe (PAGE), June 2017, Budapest, Hungary

D. Lott, T. Lehr, J. Dingemanse, A. Krause. Tolerance modeling: effects of the selective S1P1 receptor modulator ponesimod on heart rate. 26th Population Approach Group Europe (PAGE), June 2017, Budapest, Hungary

N. Hanke, S. Frechen, T. Eissing, T. Wendl, T. Lehr. Physiologically-based pharmacokinetic (PBPK) modeling of alfentanil as a CYP3A4 victim drug. 26th Population Approach Group Europe (PAGE), June 2017, Budapest, Hungary

P. Balazki, V. Woerle, S. Schaller, T. Eissing, T. Lehr. Physiologically-based pharmacokinetics/pharmacodynamics model of dapagliflozin, an oral SGLT2 inhibitor. 26th Population Approach Group Europe (PAGE), June 2017, Budapest, Hungary

J.G. Wojtyniak, K.M. Götz, T. Lehr. The benefits of a one-page summary sheet (OPSS) compared to the patient information leaflet (PIL) to enhance health literacy – a randomized crossover trial. Annual meeting of the German Pharmaceutical Society (DPhG), 2017, Saarbrücken, Germany

K.M. Götz, J.G. Wojtyniak, T. Lehr. Package information leaflets (PILs) fail to inform patients – a study on the readability of PILs. Annual meeting of the German Pharmaceutical Society (DPhG), 2017, Saarbrücken, Germany

N. Scherer, C. Dings, T. Lehr. Smartphone compliance apps in praxis: how reliably can a medication plan be entered? Annual meeting of the German Pharmaceutical Society (DPhG), 2017, Saarbrücken, Germany

A.K. Volz, A. Krause, J. Dingemanse T. Lehr. Target-mediated drug disposition as a potential class effect of endothelin receptor antagonists - pharmacokinetic modelling of bosentan, clazosentan, and tezosentan in healthy subjects. Annual meeting of the German Pharmaceutical Society (DPhG), 2017, Saarbrücken, Germany

P. Balazki, T. Eissing, T. Lehr. Medication review in hematopoietic stem cell transplanted patients. Annual meeting of the German Pharmaceutical Society (DPhG), 2017, Saarbrücken, Germany

H. Britz, N. Hanke, T. Lehr. Physiologically-based pharmacokinetic (PBPK) modeling of dronedarone and its main metabolite N-debutyldronedarone. Annual meeting of the German Pharmaceutical Society (DPhG), 2017, Saarbrücken, Germany

2016

C. Dings, T. Lehr. Pharmacokinetic and pharmacodynamic modeling of acetylsalicylic acid and its major metabolite salicylic acid. 25th Population Approach Group Europe (PAGE), June 2016, Lisbon, Portugal

N. Scherer, C. Dings, M. Böhm, U. Laufs, T. Lehr. Pharmacokinetic and pharmacodynamic modeling of alirocumab and evolocumab, two fully human monoclonal antibodies targeting PCSK9. 25th Population Approach Group Europe (PAGE), June 2016, Lisbon, Portugal

J.G. Wojtyniak, J. Liebl, T. Lehr. A cancer cell cycle model to predict effects of combination therapy and different dosing schedules on cell cycle, tumor growth and therapy outcome. 25th Population Approach Group Europe (PAGE), June 2016, Lisbon, Portugal

H. Britz, D. Moj, N. Hanke, T. Lehr. Physiologically-based pharmacokinetic (PBPK) modeling of the dronedarone drug-drug interaction with digoxin. 25th Population Approach Group Europe (PAGE), June 2016, Lisbon, Portugal

D. Lott, J. Dingemanse, T. Lehr, A. Krause. Population pharmacokinetics of the selective S1P1 receptor modulator ponesimod. 25th Population Approach Group Europe (PAGE), June 2016, Lisbon, Portugal

N. Hanke, S. Frechen, H. Britz, D. Moj, T. Kanacher, T. Eissing, T. Wendl, T. Lehr. Physiologically-based pharmacokinetic modeling of rifampicin drug-drug interactions with midazolam and digoxin. 25th Population Approach Group Europe (PAGE), June 2016, Lisbon, Portugal

2015

M.I. Titze, O. Schaaf, M.H. Hofmann, M. Sanderson, S. Zahn, J. Quant, T. Lehr. Allometric scaling of the pharmacokinetics of BI 893923, a novel IGF-1 receptor inhibitor. CESAR Annual Meeting, September 2015, Innsbruck, Austria

N. Schaefer, J.G. Wojtyniak, M. Kettner, J. Schlote, M.W. Laschke, A.H. Ewald, T. Lehr, M.D. Menger, H.H. Maurer, P.H. Schmidt. Pharmacokinetic modelling of JWH-10, RCS-4, and THC in pig serum after intravenous administration. Annual Meeting of The International Association of Forensic Toxicologists (TIAFT), August 2015, Florence, Italy

M.I. Titze, O. Schaaf, M.H. Hofmann, M. Sanderson, S. Zahn, J. Quant, T. Lehr. PK/PD modeling of biomarker modulation and tumor growth inhibition by BI 893923, a novel IGF-1 receptor inhibitor. 24th Population Approach Group Europe (PAGE), June 2015, Hersonissos, Greece

D. Moj, A. Schäftlein, N. Hanke, W. Braun, M.J. Müller, T. Lehr. Is the ICRP reference man still suitable for physiologically-based pharmacokinetic (PBPK) modeling? 24th Population Approach Group Europe (PAGE), June 2015, Hersonissos, Greece

D. Lott, J. Dingemanse, M. Hoch, T. Lehr, A. Krause. Population pharmacokinetics of the selective S1P1 receptor modulator ponesimod and its primary metabolites in healthy and organ-impaired subjects. 24th Population Approach Group Europe (PAGE), June 2015, Hersonissos, Greece

2014

C. Dings, A. Schäftlein, T. Lehr. Predicting the impact of oral anticoagulants on the human coagulation pathway using a comprehensive systems pharmacology model. Annual meeting of the German Pharmaceutical Society (DPhG), 2014, Frankfurt, Germany

Schäftlein, H. Maas, P.A. Reilly, A. Staab, T. Lehr. Population modeling of the relationship between the pharmacokinetics of the oral thrombin inhibitor dabigatran etexilate and coagulation biomarkers in patients with non-valvular atrial fibrillation from the RE-LY trial. 23rd Population Approach Group Europe (PAGE), June 2014, Alicante, Spain

M.I. Titze, M. Ehrhardt, S. Smola, N. Graf, T. Lehr. A semi-mechanistic model to describe the bidirectional interaction between oncolytic reovirus and in vitro tumor growth of U87-glioblastoma cells. 23rd Population Approach Group Europe (PAGE), June 2014, Alicante, Spain

D. Moj, T. Kanacher, T. Wendl, S. Willman, T. Lehr. Physiologically-based Pharmacokinetic (PBPK) modeling of the time-dependent drug-drug interaction (DDI) of clarithromycin and midazolam. 23rd Population Approach Group Europe (PAGE), June 2014, Alicante, Spain

2013

D. Moj, K. Thelen, S. Willman, T. Lehr. Physiologically-based pharmacokinetic (PBPK) model of clarithromycin. Annual meeting of the German Pharmaceutical Society (DPhG), 2013, Freiburg, Germany

M.I. Titze, M. Ehrhardt, S. Smola, N. Graf, T. Lehr. A semi-mechanistic mathematical model to describe the effect of oncolytic reovirus on in vitro tumor cell growth of U87-glioblastoma cells. Annual meeting of the German Pharmaceutical Society (DPhG), 2013, Freiburg, Germany

K. Dietel, T. Gampfer, J. Stingl, T. Lehr. Personalized pharmacotherapy through pharmacogenetic testing in Germany – obstacles and opportunities. Annual meeting of the German Pharmaceutical Society (DPhG), 2013, Freiburg, Germany

I. Schneider, H. Britz, M.I. Titze, T. Lehr. A study to assess the accuracy and precision of the digitizing software GetData Graph Digitizer. Annual meeting of the German Pharmaceutical Society (DPhG), 2013, Freiburg, Germany

J.D. Gómez-Mantilla, U.F. Schaefer, T. Lehr, V.G. Casabó, C.M. Lehr. Tailor-made dissolution profile comparisons using in vitro-in vivo correlation models. 22nd Population Approach Group Europe (PAGE), June 2013, Glasgow, Scotland

K.H. Liesenfeld, A. Staab, S. Haertter, S. Formella, A. Clemens, T. Lehr. Pharmacometric characterization of the elimination of dabigatran by haemodialysis. 22nd Population Approach Group Europe (PAGE), June 2013, Glasgow, Scotland

K.G. Haug, A. Staab, T. Lehr. Development and validation of a semi-physiological model of Amyloid-β biosynthesis and clearance in human cerebrospinal fluid including the impact of the Gamma-Secretase inhibitor semagacestat. Annual Meeting ASCPT, March 2013, Indianapolis, IN, USA

2005 - 2012

K.H. Liesenfeld, T. Lehr, V. Moschetti, S. Formella, A. Clemens, A. Staab, S. Haertter. Modelling and simulation of redistribution of dabigatran after elimination by haemodialysis in patients with end stage renal disease (ESRD). XXIII Congress of the ISTH, July 2011, Kyoto, Japan

K.H. Liesenfeld, T. Lehr, V. Moschetti, S. Formella, A. Clemens, A. Staab, S. Haertter. Modeling and simulation to optimise the study design investigating the hemodialysis of dabigatran in patients with end stage renal disease (ESRD). 20th Population Approach Group Europe (PAGE), June 2011, Athens, Greece

T. Lehr, H.G. Schaefer, A. Staab. High-throughput genotyping data joins pharmacometric analysis: An algorithm for the successful integration. Annual meeting of the American Association of Pharmaceutical Scientists (AAPS), November 2009, Los Angeles, CA, USA

C. Dansirikul, A. Staab, L. Salin, S. Haertter, T. Lehr.  Population pharmacokinetic analysis of pramipexole extended-release formulation in Parkinson’s Disease (PD) patients. 18th Population Approach Group Europe (PAGE), June 2009, St. Petersburg, Russia

R. Hauser, O. Rascol, P. Barone A. Schapira, W. Powe, Y. Mizuno, C. Dansirikul, A. Staab, T. Lehr, S. Haertter. Pharmacokinetic profiling of pramipexole extended-release in Parkinson’s disease (PD): implications for dosing in PD patients with renal insufficiency. 13th International Congress of Parkinson's Disease and Movement Disorders, June 2009, Paris, France

C. Dansirikul, R. Hauser, A. Staab, T. Lehr, S. Haertter. Population pharmacokinetic analysis of pramipexole extended-release formulation in patients with Parkinson’s disease. 61st American Academy of Neurology (AAN) Annual Meeting, May 2009, Seattle, WA, USA

T. Lehr, A. Staab, C. Tillmann, D. Trommeshauser, A. Raschig, H.G. Schaefer, C. Kloft. Efficacy modelling of NS2330 in mild Alzheimer’s disease patients. 15th Population Approach Group Europe (PAGE), June 2006, Bruges, Belgium

T. Lehr, A. Staab, C. Tillmann, D. Trommeshauser, A. Raschig, H.G. Schaefer, C. Kloft. Population pharmacokinetics of NS2330 and its major metabolite in Alzheimer’s disease patients. 15th Population Approach Group Europe (PAGE), June 2006, Bruges, Belgium

D. Zeumer, A. Staab, T. Lehr, C. Tillmann, K.H. Liesenfeld, H.G. Schaefer. PROPHET - A convenient and efficient environment for the use of NONMEM in a global pharmaceutical company. 15th Population Approach Group Europe (PAGE), June 2006, Bruges, Belgium

T. Lehr, C. Tillmann, A. Staab, D. Trommeshauser, H.G. Schaefer, C. Kloft: Estimating the maximum impact of CYP3A4 inhibition on the pharmacokinetics of long half-life drugs: a mechanistic modelling approach. Annual meeting of the American Association of Pharmaceutical Scientists (AAPS), November 2005, Nashville, TN, USA